BlueRock Therapeutics Ballroom

FEATURED FIRESIDE CHAT: BREXIT’S EFFECT ON CELL AND GENE THERAPY REGULATION {BlueRock Therapeutics Ballroom}
10:45am – 11:15am

PANEL: MYTH VS. REALITY – IMPLEMENTING PAYMENT ARRANGEMENTS FOR CELL AND GENE THERAPIES {BlueRock Therapeutics Ballroom}
1:15pm – 2:15pm
Payers and therapeutic developers are starting to implement payment-over-time and pay-for-performance arrangements. Where does the reality on the ground diverge from common perception? What role are third parties playing today and what needs to change in order for these arrangements to be widespread?

PANEL: CELL AND GENE THERAPY FOR NEUROLOGICAL PRODUCT INDICATIONS {BlueRock Therapeutics Ballroom}
4:00pm – 5:00pm
Durable treatments for the complex range of diseases affecting the central nervous system have long been an area of focus for the medical community. With advances in gene and cell therapy, there is a growing range of therapeutic strategies which may provide long awaited relief to myriad patient populations. This panel will review the state of development and clinical progress for these next-generation durable treatments for CNS conditions.

PANEL: CLINICIANS WORKING WITH CAR-T THERAPIES {BlueRock Therapeutics Ballroom}
9:15am – 10:15am
Thousands of patients have now been treated with CAR-T therapies. Find out what unique challenges and rewards come with providing these treatments from those on the front lines, and learn what the experience to date suggests about the widespread use of CAR-T.

FEATURED SPEAKER: ADVANCING GENE THERAPIES GREAT AND SMALL {BlueRock Therapeutics Ballroom}
10:45am – 11:15am

PANEL: WHEN DOES INVESTING IN CELL AND GENE THERAPY MAKE BUSINESS SENSE? {BlueRock Therapeutics Ballroom}
11:15am – 12:15pm
The cell and gene therapy industry is undergoing a critical inflection point as is evident in large financing deals, exciting clinical data and landmark regulatory approvals. However assets also face challenges such as high development costs and significant manufacturing complexities. Through a presentation and panel discussion, this session will define drivers of cost of development and cost of goods and provide a framework for assessing investment potential of cell and gene therapy assets.

SPOTLIGHT SESSION: THE EVOLUTION OF CELL AND GENE THERAPY IN CHINA {BlueRock Therapeutics Ballroom}
1:30pm – 2:00pm
Senior executives active in the region will share their experience and outlook on the cell and gene therapy industry in China, with advice for those considering expansion or are new to the market.

PANEL: THE IMPACT OF UNIVERSAL DONOR CELLS AND iPSCs ON THE CELL THERAPY INDUSTRY {BlueRock Therapeutics Ballroom}
3:15pm – 4:15pm
Since the discovery of pluripotent stem cells in the early 1980’s, the promise of fit-to-purpose cell replacement therapy has occupied the imaginations of many in the medical and patient communities. Progress was slowed by both technical and ethical challenges, but with the discovery of the iPSC source in 2006, many of these hurdles were overcome and the pace of research and clinical development accelerated dramatically. Further, genetic and biomaterials modification to this limitless supply of cells has opened new doors to allogeneic stem cell-derived cell therapy, including the associated promise of lower costs and higher accessibility. This panel will explore the ways in which iPSCs, and more specifically iPSCs modified for allogeneic use, have changed the way in which we think about the commercial viability of cell therapies.

FEATURED SPEAKERS: EMILY WHITEHEAD’S JOURNEY TO CAR-T – NO LIVESTREAM AT THIS TIME {BlueRock Therapeutics Ballroom}
9:15am – 9:45am

PANEL: A LOOK INTO THE CRYSTAL BALL – WHAT DOES THE FUTURE HOLD FOR GENE EDITING? {BlueRock Therapeutics Ballroom}
9:45am – 10:45am
This dynamic panel discussion featuring executives from leading gene editing companies will explore the major milestones and advances anticipated in the near term (12 month), midterm (5 year), and long term (10+ year) timeframes for these promising therapies. This session will also consider how the rapidly evolving climate surrounding these technologies will potentially impact the future of the sector’s success.

PANEL: INNOVATION AROUND MANUFACTURING TECHNOLOGIES {BlueRock Therapeutics Ballroom}
11:00am – 12:00pm
In biotechnology, a good idea born in a lab too often fails to make it to clinical and commercial reality due to challenges in scalability, production, and characterization. For cell, gene, and tissue engineered products these challenges are particularly acute. It has even reached the point in which investors have begun seek a scalable platform over a promising idea. This panel will explore the next-generation technologies enabling the scalable, transferable, and cost-effective manufacture of regenerative medicine products and discuss the ways in which the regenerative medicine industry must continue to develop fit-for-purpose platforms to address sector specific CMC challenges.